Agile therapeutics receives $4.7m after selling net operating loss tax benefits through new jersey economic development program

Princeton, n.j., april 11, 2022 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx), a women's healthcare company, today announced the receipt of $4.7 million in net proceeds from the sale of tax benefits pursuant to the company's participation in the new jersey economic development authority (njeda) net operating loss (nol) program under the new jersey economic recovery act of 2020.
AGRX Ratings Summary
AGRX Quant Ranking